A nurse is collecting data on a client who has obstructive sleep apnea. Which of the following findings should the nurse expect?

A. Liver function tests

This is the correct choice. Pyrazinamide, a medication used in the treatment of tuberculosis, is known to potentially cause hepatotoxicity, which refers to liver damage or dysfunction. Therefore, clients prescribed pyrazinamide should undergo regular monitoring of liver function tests to assess for any signs of liver injury or impairment. Liver function tests typically include measurements of various enzymes and proteins produced by the liver, such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and bilirubin levels.

B. Gallbladder studies

Gallbladder studies are not typically indicated for clients taking pyrazinamide. While pyrazinamide can rarely cause hepatotoxicity, which may affect liver function, it is not known to specifically target or affect the gallbladder. Therefore, routine gallbladder studies are not necessary for clients taking pyrazinamide.

C. Thyroid function studies

Pyrazinamide is not known to directly affect thyroid function. Therefore, routine thyroid function studies are not indicated for clients taking pyrazinamide unless there are specific signs or symptoms suggesting thyroid dysfunction.

D. Blood glucose levels

Pyrazinamide is not known to directly affect blood glucose levels. Therefore, routine monitoring of blood glucose levels is not indicated for clients taking pyrazinamide unless there are specific reasons to suspect or monitor for diabetes mellitus or other conditions affecting blood glucose regulation.

A. Treatment is not needed if the client is asymptomatic.

Even asymptomatic pulmonary embolisms can lead to complications such as progression to symptomatic PE or development of chronic thromboembolic pulmonary hypertension. Therefore, treatment is necessary to prevent these complications.

B. Treatment is not needed if the pulmonary embolism is intermediate.

The severity of a pulmonary embolism is determined by various factors, including the size and location of the clot and the degree of obstruction in the pulmonary arteries. Intermediate-risk pulmonary embolisms still require treatment to prevent complications and reduce the risk of progression to a more severe or life-threatening condition.

C. Treatment is not needed if the client is hemodynamically stable.

Hemodynamic stability refers to the client's circulatory status and whether they are maintaining adequate blood flow to vital organs. While hemodynamically stable clients may not require aggressive interventions such as thrombolytic therapy or surgical embolectomy, they still require anticoagulant therapy to prevent further clot formation and reduce the risk of complications.

D. Treatment is needed for all clients who have a pulmonary embolism.

Pulmonary embolism (PE) is a serious and potentially life-threatening condition that requires prompt treatment. Regardless of the severity of symptoms or the client's hemodynamic stability, treatment is necessary to prevent complications and reduce the risk of recurrence. Treatment typically includes anticoagulant therapy to prevent further clot formation and may include additional interventions such as thrombolytic therapy or surgical interventions in certain cases.